ONC · BeOne Medicines Ltd.
$347.48
-8.53 (-2.40%)
At close · Aug 14
Market Cap
$513.62B
Shares
1.48B
BeOne Medicines Ltd. Earnings Call Transcripts
Every quarterly earnings call for BeOne Medicines Ltd. (ONC) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲74.3%
$595.26M
−$381.14M
'23 Q2
23-08-02
▲28.2%
$1.00B
−$121.35M
'24 Q3
24-12-16
▲77.8%
$1.13B
−$151.88M
'24 Q4
25-02-27
▲48.6%
$1.12B
$1.27M
'25 Q1
25-05-07
▲41.6%
$1.32B
$94.32M
'25 Q2
25-08-06
▲41%
$1.41B
$124.84M
'25 Q3
25-11-06
▲32.8%
$1.50B
$66.50M
'25 Q4
26-02-26
▲35.5%
$1.51B
$227.36M
'26 Q1
26-05-06
LATEST
▲29.6%
$1.71B
$237.01M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
BeOne Medicines Ltd. Q2 FY2026 Earnings Call
Revenue
$1.71B
▲ 29.6% YoY Diluted EPS
$0.16
▲ 166.7% YoY Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference at 10:00 AM ET
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
BeOne Medicines Ltd. Q1 FY2026 Earnings Call
Revenue
$1.51B
▲ 35.5% YoY Diluted EPS
$0.15
Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
BeOne Medicines Ltd. Q4 FY2025 Earnings Call
Confident tone
BRUKINSA franchise leadership in CLL
Fixed-duration vs continuous treatment dynamics
Pipeline progress and R&D momentum
Revenue
$1.50B*
▲ 32.8% YoY Gross margin
90.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
BeOne Medicines Ltd. Q3 FY2025 Earnings Call
Confident tone
Sonro (BCL2 inhibitor) and zanu+sonro combination
BRUKINSA commercial momentum and global leadership
ASH 2025 data presentations and scientific leadership
Revenue
$1.41B
▲ 41% YoY Diluted EPS
$0.08
Gross margin
86.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
BeOne Medicines Ltd. Q2 FY2025 Earnings Call
Confident tone
BRUKINSA commercial leadership
CLL franchise and ALPINE data
Financial results and cash flow
Revenue
$1.32B
▲ 41.6% YoY Diluted EPS
$0.06
Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
BeOne Medicines Ltd. Q1 FY2025 Earnings Call
Confident tone
Global commercial expansion
BRUKINSA commercial leadership
Pipeline progression
Revenue
$1.12B
▲ 48.6% YoY Diluted EPS
$0.00
Gross margin
85.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
BeOne Medicines Ltd. Q4 FY2024 Earnings Call
Revenue
$1.13B*
▲ 77.8% YoY Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-16
BeOne Medicines Ltd. Q3 FY2024 Earnings Call
Revenue
$1.00B
▲ 28.2% YoY Diluted EPS
$-0.09
▼ 160% YoY Gross margin
83.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
BeOne Medicines Ltd. Q2 FY2023 Earnings Call
Revenue
$595.26M
▲ 74.3% YoY Diluted EPS
$-0.28
Gross margin
83.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
288 filings
263 filers
Visit website
Investor relations